Scholarlink

Background <p>Melanoma represents a highly aggressive and immunotherapy-resistant malignancy with limited immunotherapy efficacy, underscoring the urgent need for novel treatment strategies that integrate precise diagnosis and potent immunomodulation. The combination of photothermal therapy (PTT) and STING pathway activation has emerged as a promising approach to potentiate antitumor immunity. Nevertheless, it remains challenging to integrate real-time deep-tissue imaging with spatiotemporally synchronized immunostimulation within a single nanoplatform, especially for the effective treatment of advanced melanoma.</p> Results <p>Herein, we report a mitochondria-targeted nanotheranostic agent (IRM) constructed through molecular co-assembly of a STING agonist (MSA-2) and a lab-synthesized NIR-Ⅱ fluorophore (IR-817). This nanoplatform enables simultaneous NIR-Ⅱ fluorescence imaging and high-efficiency photothermal conversion (η = 52.79%). More importantly, it ensures efficient, on-demand drug action through spatiotemporally controlled delivery. Under 808&#xa0;nm laser irradiation, IRM induced localized hyperthermia that provoked pyroptosis and immunogenic cell death (ICD) in primary melanoma tumors. Concurrently, the photothermal stimulus promoted the rapid release of MSA-2, which synergistically activated the STING pathway in dendritic cells (DCs). This event drove immunometabolic reprogramming of the tumor microenvironment, elicited a robust systemic cytotoxic T-cell response, and effectively reversed the immunosuppressive state. This cascade of biological events ultimately led to significant inhibition of distant tumors, demonstrating a robust abscopal effect. Crucially, this therapeutic effect was strictly STING-dependent: in <i>STING</i>-KO mouse models, the suppression of distant tumors was completely abolished following the same treatment. These complementary experimental outcomes directly confirm the indispensable synergy between PTT and STING pathway activation, which together constitute the core mechanism underlying the induction of systemic antitumor immunity by the IRM nanoplatform.</p> Conclusions <p>Our study illustrates that the IRM nanoplatform effectively merges multimodal imaging with immunometabolic modulation, establishing a durable and systemic antitumor immunity. This work offers a translatable strategy for combinational photo-immunotherapy against advanced melanoma.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A NIR-Ⅱ-Immunostimulatory nanoplatform rewires immunometabolism to unleash STING-driven antitumor immunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月15日

查看全文
  • Xun Yang,
  • Xuefeng Chen,
  • Minhao Chen,
  • Simei Yang,
  • Ya Wu,
  • Hongye Liao,
  • Tong Xia,
  • Gaoyang Shen,
  • Changzhen Sun,
  • Li Liu

摘要

Background

Melanoma represents a highly aggressive and immunotherapy-resistant malignancy with limited immunotherapy efficacy, underscoring the urgent need for novel treatment strategies that integrate precise diagnosis and potent immunomodulation. The combination of photothermal therapy (PTT) and STING pathway activation has emerged as a promising approach to potentiate antitumor immunity. Nevertheless, it remains challenging to integrate real-time deep-tissue imaging with spatiotemporally synchronized immunostimulation within a single nanoplatform, especially for the effective treatment of advanced melanoma.

Results

Herein, we report a mitochondria-targeted nanotheranostic agent (IRM) constructed through molecular co-assembly of a STING agonist (MSA-2) and a lab-synthesized NIR-Ⅱ fluorophore (IR-817). This nanoplatform enables simultaneous NIR-Ⅱ fluorescence imaging and high-efficiency photothermal conversion (η = 52.79%). More importantly, it ensures efficient, on-demand drug action through spatiotemporally controlled delivery. Under 808 nm laser irradiation, IRM induced localized hyperthermia that provoked pyroptosis and immunogenic cell death (ICD) in primary melanoma tumors. Concurrently, the photothermal stimulus promoted the rapid release of MSA-2, which synergistically activated the STING pathway in dendritic cells (DCs). This event drove immunometabolic reprogramming of the tumor microenvironment, elicited a robust systemic cytotoxic T-cell response, and effectively reversed the immunosuppressive state. This cascade of biological events ultimately led to significant inhibition of distant tumors, demonstrating a robust abscopal effect. Crucially, this therapeutic effect was strictly STING-dependent: in STING-KO mouse models, the suppression of distant tumors was completely abolished following the same treatment. These complementary experimental outcomes directly confirm the indispensable synergy between PTT and STING pathway activation, which together constitute the core mechanism underlying the induction of systemic antitumor immunity by the IRM nanoplatform.

Conclusions

Our study illustrates that the IRM nanoplatform effectively merges multimodal imaging with immunometabolic modulation, establishing a durable and systemic antitumor immunity. This work offers a translatable strategy for combinational photo-immunotherapy against advanced melanoma.

Graphical Abstract